OSL GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.26 HKD | +1.15% |
|
-2.05% | -56.74% |
| Jun. 17 | Osl Group Limited Announces Appointment of Yang Huan Independent Non-Executive Directors | CI |
| Jun. 03 | Oncosil Medical Treats 200th Pancreatic Cancer Patient with Proprietary Device | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 5,094 | 3,104 | 1,208 | 4,846 | 3,059 | - |
| Enterprise Value (EV) 1 | 5,094 | 2,195 | 275.4 | 4,644 | 2,137 | 2,128 |
| P/E ratio | -19.2 x | - | -2.46 x | -19.6 x | -26 x | -88.8 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 10.8 x | 11.9 x | 25 x | 9.52 x | 7.19 x |
| EV / Revenue | - | 7.67 x | 2.71 x | 23.9 x | 6.65 x | 5 x |
| EV / EBITDA | - | -9.91 x | -0.7 x | -27.4 x | -22.1 x | -96.4 x |
| EV / FCF | - | - | - | - | -70.4 x | 386 x |
| FCF Yield | - | - | - | - | -1.42% | 0.26% |
| Price to Book | - | 2.99 x | 1.98 x | 3.87 x | 3.34 x | 3.47 x |
| Nbr of stocks (in thousands) | 336,621 | 423,247 | 438,453 | 438,453 | 626,353 | - |
| Reference price 2 | 15.13 | 7.333 | 2.756 | 11.05 | 4.884 | 4.884 |
| Announcement Date | 4/28/21 | 3/29/22 | 3/28/23 | 3/27/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 286.2 | 101.5 | 194.1 | 321.4 | 425.8 |
| EBITDA 1 | - | -221.6 | -391.5 | -169.4 | -96.6 | -22.08 |
| EBIT 1 | - | -272.2 | -444.4 | -205.1 | -117.8 | -43.79 |
| Operating Margin | - | -95.11% | -438.03% | -105.69% | -36.66% | -10.29% |
| Earnings before Tax (EBT) 1 | - | - | -480.7 | -232.7 | -115.9 | -40.48 |
| Net income 1 | -247.8 | - | -473.8 | -243.7 | -117.3 | -34.41 |
| Net margin | - | - | -467.04% | -125.58% | -36.49% | -8.08% |
| EPS 2 | -0.7900 | - | -1.121 | -0.5635 | -0.1880 | -0.0550 |
| Free Cash Flow 1 | - | - | - | - | -30.36 | 5.52 |
| FCF margin | - | - | - | - | -9.44% | 1.3% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/28/21 | 3/29/22 | 3/28/23 | 3/27/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 909 | 933 | 202 | 922 | 931 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | - | -30.4 | 5.52 |
| ROE (net income / shareholders' equity) | - | -55.1% | -58% | - | - | - |
| ROA (Net income/ Total Assets) | - | - | -14.4% | - | - | - |
| Assets 1 | - | - | 3,296 | - | - | - |
| Book Value Per Share 2 | - | 2.450 | 1.390 | 2.850 | 1.460 | 1.410 |
| Cash Flow per Share | - | -0.8800 | - | - | - | - |
| Capex 1 | - | - | - | - | 22.1 | 29.4 |
| Capex / Sales | - | - | - | - | 6.87% | 6.91% |
| Announcement Date | 4/28/21 | 3/29/22 | 3/28/23 | 3/27/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.884
CNY
Average target price
6.072
CNY
Spread / Average Target
+24.32%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -56.74% | 422M | |
| +25.36% | 53.54B | |
| +50.31% | 9.06B | |
| +72.10% | 2.3B | |
| +146.20% | 419M | |
| +24.13% | 411M | |
| -55.94% | 307M | |
| -.--% | 121M | |
| -66.06% | 118M | |
| -37.29% | 87.95M |
- Stock Market
- Equities
- 863 Stock
- Financials OSL Group Limited
